Trial Profile
An open label study to evaluate the safety and reduction in signs and symptoms during treatment with tocilizumab in patients with moderate to severe active rheumatoid arthritis
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 09 Nov 2021
Price :
$35
*
At a glance
- Drugs Tocilizumab (Primary)
- Indications Rheumatoid arthritis
- Focus Registrational; Therapeutic Use
- 16 Aug 2010 Actual end date (Jul 2010) added as reported by ClinicalTrials.gov.
- 10 Aug 2010 Status changed from active, no longer recruiting to completed as reported by Roche.
- 20 Jun 2009 New source identified and integrated (Roche, ML22074).